Quicksilver Scientific

Free shipping over $50

0

Unsupported Browser

This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.

CBD Synergies AX References

  1. Pacher P et al. Modulating the endocannabinoid system in human health and disease–successes and failures. FEBS J. 2013 May;280(9):pp. 1918-43 View Full Paper
  2. McPartland JM et al. Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system. PLoS One. 2014;9(3):e89566 View Full Paper
  3. Di Marzo V et al. FAAH and anandamide: is 2-AG really the odd one out? Trends Pharmacol Sci. 2008; 29:229–233. View Abstract
  4. Matsuda LA et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990; 346: pp. 561-564 View Abstract
  5. Munro S et al. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993; 365: pp. 61-65 View Abstract
  6. Devane WA et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 992; 258: pp. 1946–1949 View Abstract
  7. Morales P, et al. Molecular targets of the phytocannabinoids. Prog Chem Org Nat Prod. 2017;103:103-131 View Abstract
  8. Citti C et al. Medicinal cannabis: Principal cannabinoids concentration and their stability evaluated by a high performance liquid chromatography coupled to diode array and quadrupole time of flight mass spectrometry method.J Pharm Biomed Anal. 2016 Sep 5;128:201-209 View Abstract
  9. Turner SE. Molecular pharmacology of phytocannabinoids. Prog Chem Org Nat Prod. 2017;103:61-101 View Abstract
  10. Ligresti A. From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology. Physiol Rev. 2016 Oct;96(4):1593-659 View Full Paper
  11. Mechoulam R. Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol. 2002 Nov;42(S1):11S-19S. View Abstract
  12. El-Alfy AT et al. Antidepressant-like effect of19 -tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacol. Biochem. Behav. 2010; 95, pp. 434–442 View Full Paper
  13. Ashton CH et al. Endocannabinoid system dysfunction in mood and related disorders. Acta Psychiatr Scand. 2011 Oct;124(4): pp. 250-61 View Abstract
  14. Korem N et al. Targeting the endocannabinoid system to treat anxiety-related disorders. J Basic Clin Physiol Pharmacol. 2016 May 1;27(3): pp. 193-202 View Full Paper
  15. Blessing EM et al. Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics. 2015 Oct; 12(4): pp. 825–836 View Full Paper
  16. Mandolini GM et al. Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview. Epidemiol Psychiatr Sci. 2018 Aug;27(4):327-335 View Abstract
  17. Soares VP et al. Evidences for the antipanic actions of cannabidiol. Current Neuropharmacology 2017; 15, 291–299 View Full Paper
  18. Crippa JAS et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. Journal of Psychopharmacology 2011; 25, 121–130. View Abstract
  19. Linares IMP et al. No acute effects of cannabidiol on the sleep-wake cycle of healthy subjects: a randomized, double-blind, placebo controlled, crossover study. Front Pharmacol. 2018 Apr 5;9:315. View Full Paper
  20. Baldwin D et al. The role of serotonin in depression and anxiety. Int Clin Psychopharmacol. 1995 Jan;9 Suppl 4:41-5 View Abstract
  21. Birdsall TC. 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Altern Med Rev. 1998 Aug;3(4):271-80 View Full Paper
  22. Möhler H. The GABA system in anxiety and depression and its therapeutic potential Neuropharmacology. 2012 Jan;62(1):42-53. doi: 10.1016/j.neuropharm.2011.08.040. View Abstract
  23. Lydiard RB. The role of GABA in anxiety disorders. J Clin Psychiatry. 2003;64 Suppl 3:21-7 View Full Paper
  24. Abdou AM.  Relaxation and immunity enhancement effects of gamma-aminobutyric acid (GABA) administration in humans Biofactors. 2006;26(3):201-8 View Abstract
  25. Yoto A. Oral intake of γ-aminobutyric acid affects mood and activities of central nervous system during stressed condition induced by mental tasks. Amino Acids. 2012 Sep;43(3):1331-7. View abstract
  26. Mazzoli R et al. The neuro-endocrinological role of microbial glutamate and GABA signaling. Front Microbiol. 2016 Nov 30;7:1934  View Full Paper
  27. Haskell CF et al.  The effects of L-theanine, caffeine and their combination on cognition and mood. Biol.Psychol. 2008;77(2):113-122 View Abstract
  28. Kimura K et al. L-Theanine reduces psychological and physiological stress responses. Biol Psychol. 2007;74(1):39–45. View Abstract
  29. Nathan PJ et al. The neuropharmacology of L-theanine(N-ethyl-L-glutamine): a possible neuroprotective and cognitive enhancing agent. J Herb Pharmacother. 2006;6(2):21-30. View Abstract
  30. Shi Y. Herbal insomnia medications that target GABAergic systems: a review of the psychopharmacological evidence. Curr Neuropharmacol. 2014 May;12(3):289-302. View Full Paper
  31. Hui KM, et al. Anxiolytic effect of wogonin, a benzodiazepine receptor ligand isolated from Scutellaria baicalensis Georgi. Biochem Pharmacol. 2002; 64(9): 1415-1424.
  32. Dantas LP. Effects of passiflora incarnata and midazolam for control of anxiety in patients undergoing dental extraction Med Oral Patol Oral Cir Bucal. 2017 Jan 1;22(1):e95-e101. View Full Paper
  33. Shakeri A et al. Melissa officinalis L. – A review of its traditional uses, phytochemistry and pharmacology. J Ethnopharmacol. 2016 Jul 21;188:204-28. View Abstract
  34. Scholey A. Anti-stress effects of lemon balm-containing foods. Nutrients. 2014 Oct 30;6(11):4805-21. View Full Paper
2
Your Cart